本帖最后由 老马 于 2012-1-13 21:20 编辑 : P, P3 ~# K: a" x4 A
8 Z N3 A, S9 ~+ B3 b3 V; r
爱必妥和阿瓦斯丁的比较
, P8 G4 G' d# p# Z4 p; B$ Z$ y5 I: _3 X
! [& ^5 R) s& f4 m6 W+ q
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
7 I3 u+ `$ f& E3 N1 `* t: w) s; x
3 ~1 Q# p0 W; N
/ f1 E( V) Q6 Y, }7 bhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
% i" y) U9 u4 _==================================================
( A0 e; [% S6 \8 ?, vOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)/ Q4 l$ X$ H8 {1 c) Q% U
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.' T# a1 H! i: w6 U5 T& y9 W
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.: b. M Z- L& _9 [1 Q: ~- W
|
显身卡
